Highlight Therapeutics Presents Positive Phase 2b Topline Results of Intralesional BO-112 in Localized Basal Cell Carcinoma as a Late-Breaker at EADV

Highlight Therapeutics SL published this content on October 23, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 23, 2026 at 13:08 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]